Kerri-Ann Limbeek

I'll research Kerri-Ann Limbeek's professional background before drafting.

Let me verify the tracked docket appearances and the recent trials.

Kerri-Ann Limbeek — Partner, Desmarais LLP (New York)

Specialty / focus. Limbeek is a first-chair trial lawyer whose practice centers on complex technology and patent disputes. Her firm profile describes work spanning pharmaceuticals, medical and surgical devices, consumer products, semiconductor fabrication, computer hardware, software, telecommunications, and video streaming, with experience at the ITC, district courts, the Federal Circuit, and in ICC arbitration. The tracked docket is consistent with that breadth rather than a single technology niche: life sciences/diagnostics (the Ravgen prenatal-testing campaign), medical devices (Abiomed), consumer electronics (Apple), and voice-assistant and retail/software patents (VB Assets, Alpha Modus). Her chemistry/engineering background (see below) fits the diagnostics and device work.

Side preference. She works both sides, and the tracked counts are nearly even (3 plaintiff-side, 4 defendant-side). Her highest-profile matters have been plaintiff-side prosecution of patent-owner campaigns (Ravgen) and, separately, defense of operating companies such as Apple and Abiomed. Tracked entries show her as plaintiff-side lead counsel in Ingeniospec v. Apple and Alpha Modus v. Walgreens, and defense-side for Apple in Headwater Research and VB Assets (with one VB Assets entry listed as plaintiff-side, likely reflecting a separate or consolidated action). She is not an in-house lawyer or a dedicated NPE-side specialist; the pattern is a mixed plaintiff/defendant trial practice.

Firm context and notable results. She joined Desmarais LLP as an associate in 2015, became partner in January 2022, and previously practiced at Sullivan & Cromwell (2013–2015). Her signature matters are the Ravgen non-invasive prenatal testing cases: a $272.5 million jury verdict against LabCorp in September 2022, enhanced by $100 million for willfulness to roughly $372.5 million (she was co-lead/part of the trial team with firm founder John Desmarais), followed by a $57 million damages verdict against Natera in January 2024 in her first turn as lead trial counsel (opening and closing). The firm reports settlements with Myriad, Illumina, Quest Diagnostics, PerkinElmer, Roche, and Biora in related Ravgen suits. On the defense side, she was on the team that won a complete non-infringement verdict in the Western District of Texas in September 2024 that eliminated a $361 million encryption-patent damages claim (she handled damages and won Daubert exclusions of the plaintiff's damages theories), and she was on the Desmarais team that obtained a complete defense verdict for Abiomed in Maquet Cardiovascular v. Abiomed (D. Mass., May 2026), where the jury found no infringement under the reverse doctrine of equivalents and the asserted claim invalid for written description and enablement. The firm also reports an October 2024 plaintiff-side jury win in Wilmington, Delaware on smartwatch and charger design patents.

PTAB / IPR experience. Extensive and well documented. She oversaw Ravgen's defense against ten inter partes reviews of its prenatal-testing patents, including defeating two Quest petitions at institution and securing final written decisions upholding all challenged claims in IPRs brought by LabCorp, Illumina, and Streck; the Federal Circuit affirmed Ravgen in three appeals from those decisions. Her February 2022 pro hac vice declaration in Streck v. Ravgen (IPR2021-01577) lists prior PTAB appearances as well, including the Hologic v. Enzo Life Sciences IPRs (IPR2016-00820, -00822).

Bar / education. Admitted in New York (2014), also admitted before the Federal Circuit, the Fourth Circuit, and the E.D.N.Y. and S.D.N.Y.; J.D., University of Chicago Law School (2013); B.S.E. in Chemical and Biomolecular Engineering, University of Pennsylvania (2010).

Caveats: The firm biography and PTAB filings are the primary sources for the Ravgen, Abiomed, and Apple defense results; I could not independently verify the individual docket entries for Ingeniospec, VB Assets, Headwater Research, or Alpha Modus through search, so those role and party characterizations rest on the tracked docket data provided. One tracked entry is untitled and one duplicate VB Assets entry carries a different side label, suggesting multiple related actions.